Intraocular nano-microscale drug delivery systems for glaucoma treatment: design strategies and recent progress.

ABSTRACT: Glaucoma is a leading cause of irreversible visual impairment and blindness, affecting over 76.0 million people worldwide in 2020, with a predicted increase to 111.8 million by 2040. Hypotensive eye drops remain the gold standard for glaucoma treatment, while inadequate patient adherence to medication regimens and poor bioavailability of drugs to target tissues are major obstacles to effective treatment outcomes. Nano/micro-pharmaceuticals, with diverse spectra and abilities, may represent a hope of removing these obstacles. This review describes a set of intraocular nano/micro drug delivery systems involved in glaucoma treatment. Particularly, it investigates the structures, properties, and preclinical evidence supporting the use of these systems in glaucoma, followed by discussing the ro

SUBMITTER: Shen Y 

PROVIDER: S-EPMC9999627 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature